1. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. М.: OOO «Изд-кий дом «М-Вести», 2006.
2. Woodhed M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138–80.
3. Mandell L, Richard G et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Доступно на: http://www.thoracic.org/sections/publications/statements/pages/mtpi/idsaats-cap.html.
4. Jokinen C, Heiskanen L, Juvonen H et al. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in Eastern Europe. Clin Infect Dis 2001; 32: 1141–54.
5. Marrie TJ, Peeling RW, Fine MJ et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101: 508–15.
6. Niederman M. Cost-effective antibiotic management of community-acquired pneumonia. Eur Respir Mon 2004; 28: 198–210.
7. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia.N Engl J Med 1997; 336: 243–50.
8. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377–82.
9. Amsden GW, Amankwa K. Pneumococcal resistance: The treatment challenge. Ann Pharmacother 2001; 35 (4): 480–8.
10. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований Пегас I и Пегас II. Клин. микробиол. и антимикроб. химиотер. 2006; 8 (1): 33–47.
11. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000; 90: 223–9.
12. Hyde TB, Gay K, Stephens DS et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286: 1857–62.
13. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24: 1052–9.
14. Ho PL, Tse WS, Tsang KW et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32: 701–7.
15. Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis 2003; 36: 1132–8.
16. Guay D. Short-course antimicrobial therapy of respiratory tract infections. Drugs 2003; 63: 2169–84.
17. Barron et al. 2004. Personal communication.
18. Roson B, Carratala J, Fernandez-Sabe N et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004; 164: 502–8.
19. Kothe H, Bauer T, Marre R. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008; 32: 139–46.
20. Рачина С.А., Зайцев А.А. Фармакоэпидемиологические исследования антибактериальных препаратов при внебольничных инфекциях дыхательных путей. В кн.: Внебольничные инфекции дыхательных путей: диагностика и лечение. Руководство для врачей. М.: ООО «М-Вести», 2008; 254–71.
21. Drehobl MA, De Salvo MC, Lewis DE,
Breen JD. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005; 128 (4): 2230–7.
22. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002; 360 (9336): 835–41.
23. РОМИР Мониторинг 2007, http://ru-romir.com.
24. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Mortal. Morbid. Wkly Rep 1997; 46 (R-8).